<DOC>
	<DOCNO>NCT02149420</DOCNO>
	<brief_summary>This study design evaluate safety , tolerability , pharmacokinetics therapeutic efficacy single intravenous infusion VAY7346 monoclonal antibody pSS patient</brief_summary>
	<brief_title>PD VAY736 Patients With Primary Sjögren 's Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<criteria>INCLUSION CRITERIA : Fulfilled revised European US consensus criterion pSS ESSDAI value ≥ 6 Elevated serum titer screen ANA ( ≥ 1:160 ) Seropositive screen antiSSA and/or antiSSB antibody Stimulated whole salivary flow rate screen &gt; 0 mL/min EXCLUSION CRITERIA : Prior previous use ( specific dosages interval prior study start may apply ) : Bcell deplete therapy ( e.g. , rituximab ) , Prednisone , antiBAFF mAb , CTLA4Fc Ig ( abatacept ) , antiTNFα mAb , cyclophosphamide , azathioprine medication know cause dry mouth . Hydroxychloroquine methotrexate consistent dose ≥ 3 month prior randomization allow Active recent history clinically significant infection Vaccination within 2 month prior study History primary secondary immunodeficiency Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>primary Sjögren 's syndrome , pharmacodynamics</keyword>
</DOC>